Project Grant R21NS142762

Award Date 5/20/25
Completion Date 4/30/27
Dollars Obligated $432K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
This federal Project Grant award of $2,398,590 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate the role of altered brain microcirculation and capillary endothelial cell energetics in the development of vascular cognitive impairment and dementia (VCID) observed in Alzheimer's disease (AD) and related dementias. The multidisciplinary...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) totaling $683,367 aims to develop novel chemogenetic mouse models for studying cerebral hypoperfusion and vascular contributions to cognitive impairment and dementia (VCID). The award will support the creation of genetically-engineered mouse lines that allow for precise, adjustable control of brain pericyte contractility and capillary blood flow. This will enable in-depth...
This $631,577 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate the role of neutrophils in vascular inflammation and cognitive impairment related to Alzheimer's disease (AD) and vascular contributions to cognitive impairment and dementia (VCID). The key products and services to be delivered include: 1)...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $4,390,219 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The 3-year project aims to determine the prognostic importance of atrial myopathy for incident dementia in the oldest-old population, relate atrial myopathy progression to cognitive decline and...
The National Institute on Aging (NIA) awarded a $2,244,471 Project Grant under CFDA 93.866 (Aging Research) to Oregon Health & Science University (OHSU) to develop a first-in-class, CNS-penetrant small molecule agonist for G protein-coupled receptor 39 (GPR39) as a potential treatment for vascular cognitive impairment and dementia (VCID). The 3-year project from September 2023 to August 2026 will use in vitro and in vivo assays to identify lead compounds, determine their safety and...
This $5,949,022 federal Project Grant award was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports a collaborative research initiative, called the Jackson Laboratory (JAX)/Emory University/Columbia University/Rush University VCID Center Without Walls (CWOW), focused on identifying novel therapeutic targets to treat cerebral amyloid...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is providing $647,116 to the Regents of the University of Michigan to characterize and target a novel pathway promoting Parkinson's disease (PD) and Parkinson's disease dementia (PDD). The funded research aims to investigate how the interaction between the protease tissue...
The National Institute on Aging (NIA) awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to Regenerative Research Foundation to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebrovascular interactions for studying Alzheimer's disease-related dementias (ADRD). The project aims to generate a 3D human cell model that integrates cerebral cortical neurons, glia, vascular endothelial cells, pericytes, and microglia to improve the...
The National Institute on Aging (NIA) awarded a $234,000 Project Grant (CFDA 93.866 - Aging Research) to the Regents of the University of Michigan to develop immunocytokines for the long-term delivery of macrophage colony-stimulating factor (M-CSF) to selectively activate parenchymal border macrophages (PBMs) in the brain. The objective is to improve cerebrospinal fluid (CSF) dynamics, which could have significant potential for treating Alzheimer's disease and related neurodegenerative...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $4,361,625 to The Washington University to establish a "VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in ADRD". The project aims to leverage new technologies like multi-omics biomarkers and single-cell/spatial transcriptomics to investigate the complex mechanisms underlying cerebral small vessel disease (CSVD) and vascular...

This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to investigate a novel strategy for treating multi-infarct dementia (MID). The $431,750 award supports research to overexpress the CYP2C11 enzyme in peri-lesion astrocytes using an adeno-associated virus (AAV) approach, with the goal of enhancing cerebral blood flow and suppressing neuroinflammation to improve cognitive function in a mouse model of MID. The project, awarded to the partnership of Henry Ford Health and Michigan State University Health Sciences, will test the optimal dose of the CYP2C11-expressing AAV, evaluate the long-term effects, and validate the causal impact on cognitive function. This targeted approach seeks to provide a groundbreaking treatment for MID, the most prevalent form of vascular cognitive impairment and dementia, which currently lacks disease-modifying therapies.

Generated 6/17/25, 1:58 AM